Drug Profile

HST 003

Alternative Names: hECM:HST-003; HST-003

Latest Information Update: 18 Mar 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator PUR Biologics
Developer Histogen
Class Anti-inflammatories; Extracellular matrix proteins
Mechanism of Action Angiogenesis inducing agents; Extracellular matrix protein replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Cartilage disorders

Most Recent Events

14 Dec 2023 Discontinued - Phase-I/II for Cartilage disorders in USA (Implant)
24 Mar 2023 Histogen has patent protection for HST 003 in the US and other foreign jurisdictions, prior to March 2023
19 Jan 2023 Histogen terminates a phase I/II trial in Cartilage disorders [Implant] in USA due to difficulty in enrollment (NCT05082831)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com